Decoy Therapeutics (DCOY) Capital Expenditures (2015 - 2017)
Decoy Therapeutics (DCOY) posted quarterly Capital Expenditures of $178298.0 for Q4 2017, up 140.14% year-over-year from $74247.4 in Q4 2016, and up 250.41% quarter-over-quarter from -$118541.0 in Q3 2017.
Decoy Therapeutics (DCOY) Capital Expenditures (2015 - 2017) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Capital Expenditures for 3 consecutive years, with $178298.0 the latest figure, recorded in Q4 2017.
- In Q4 2017, Capital Expenditures rose 140.14% year-over-year to $178298.0; the TTM figure through Sep 2018 stood at $178298.0 (up 135.03% YoY), while the FY2025 annual figure was $577000.0, changed N/A from the prior year.
- Capital Expenditures climbed to $178298.0 in Q4 2017 per DCOY's latest filing, from -$118541.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $444187.0 in Q3 2016 and bottomed at -$444187.0 in Q4 2016.
- Historically, Capital Expenditures has averaged $40355.9 across 3 years, with a median of $26395.0 in 2015.
- On a YoY basis, Capital Expenditures climbed as much as 757.39% in 2016 and fell as far as 1934.29% in 2016.
- Decoy Therapeutics' Capital Expenditures stood at $230417.0 in 2015, then slumped by 292.78% to -$444187.0 in 2016, then jumped by 140.14% to $178298.0 in 2017.
- Business Quant data shows DCOY's Capital Expenditures at $178298.0 in Q4 2017, -$118541.0 in Q3 2017, and $31591.0 in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 251.02 Mn |
| 10 | Decoy Therapeutics | 1.76 Mn | 1.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 178,298.00 |
| Dec 31, 2017 | 178,298.00 |
| Sep 30, 2017 | -118,541.00 |
| Sep 30, 2017 | -118,541.00 |
| Jun 30, 2017 | 31,591.00 |
| Jun 30, 2017 | 31,591.00 |
| Mar 31, 2017 | 22,150.00 |
| Mar 31, 2017 | 22,150.00 |
| Dec 31, 2016 | -444,187.00 |
| Dec 31, 2016 | -444,187.00 |
| Sep 30, 2016 | 444,187.00 |
| Sep 30, 2016 | 444,187.00 |
| Jun 30, 2016 | -161,509.00 |
| Jun 30, 2016 | -161,509.00 |
| Mar 31, 2016 | 226,309.00 |
| Mar 31, 2016 | 226,309.00 |
| Dec 31, 2015 | 230,417.00 |
| Dec 31, 2015 | 230,417.00 |
| Jun 30, 2015 | 8,805.00 |
| Jun 30, 2015 | 8,805.00 |